

MEDETOMIDINE MIXED WITH OPIOIDS: THE SPECTRUM OF CLINICAL AND PUBLIC HEALTH IMPLICATIONS FROM OVERDOSE TO WITHDRAWAL

WC4994

AGENDA

Date: August 7th, 2025, 11am

Time	Topic	Speaker(s)
11:00-11:05	Introduction	Dr. Allison Arwady
11:05-11:15	What we know about medetomidine's involvement in overdoses in the United States	Dr. Allison Arwady
11:15-11:50	Recognition, Evaluation and Treatment of Medetomidine-associated Withdrawal	Dr. Samantha Huo and Dr. Jeanmarie Perrone
11:50-12:00	Q&A	All

OBJECTIVES

1. Recognize when medetomidine is involved in an overdose.
2. Describe how medetomidine involvement in overdose affects patient management.
3. Describe management of withdrawal when medetomidine involvement is suspected.
4. List how public health professionals and clinicians have collaborated to address overdoses involving medetomidine.

CE Origination Date: 08/07/2025

CE Expiration Date: 08/07/2025

ACCREDITATION STATEMENTS:



In support of improving patient care, The Centers for Disease Control and Prevention is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CME: The Centers for Disease Control and Prevention designates this **live** activity for a maximum of **1** AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE: The Centers for Disease Control and Prevention designates this activity for **1** nursing contact hours.

DISCLOSURE: In compliance with continuing education requirements, all planners and presenters/moderators must disclose all financial relationships, in any amount, with ineligible companies over the previous 24 months as well as any use of unlabeled product(s) or products under investigational use.

CDC, our planners, and presenters/moderators wish to disclose they have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Content will not include any discussion of the unlabeled use of a product or a product under investigational use.

CDC did not accept financial or in-kind support from ineligible companies for this continuing education activity.

The Centers for Disease Control and Prevention (CDC) complies with applicable Federal civil rights laws and does not discriminate based on race, color, national origin, age, disability, religion, or sex. To learn more visit: <https://www.hhs.gov/civil-rights/for-individuals/nondiscrimination/index.html>.

Instructions for Obtaining Continuing Education (CE)

To receive continuing education (CE) for **WC4994- Medetomidine mixed with opioids: the spectrum of clinical and public health implications from overdose to withdrawal**, please visit [CDC TRAIN](#) and search for the course in the Course Catalog using **WC4994**. Follow the steps below by **09/07/2025**.

1. Register for and complete the course.
2. Pass the post-assessment at 75%
3. Complete the evaluation.
4. Visit Your Learning to access your certificates and transcript.

The registration code is **08072025**

FEES: There are no fees for CE.